Biogen
BIIB
985 hedge funds and large institutions have $33B invested in Biogen in 2022 Q3 according to their latest regulatory filings, with 149 funds opening new positions, 275 increasing their positions, 372 reducing their positions, and 79 closing their positions.
89% more first-time investments, than exits
New positions opened: 149 | Existing positions closed: 79
69% more funds holding in top 10
Funds holding in top 10: 13 → 22 (+9)
32% more capital invested
Capital invested by funds: $25B → $33B (+$8.03B)
6% more funds holding
Funds holding: 927 → 985 (+58)
2.16% more ownership
Funds ownership: 83.1% → 85.26% (+2.2%)
7% more call options, than puts
Call options by funds: $2.02B | Put options by funds: $1.9B
26% less repeat investments, than reductions
Existing positions increased: 275 | Existing positions reduced: 372
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$260M |
| 2 |
Man Group
London,
United Kingdom
|
+$142M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$107M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$95.6M |
| 5 |
Millennium Management
New York
|
+$70.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$244M |
| 2 |
BlackRock
New York
|
-$131M |
| 3 |
IIM
INTECH Investment Management
West Palm Beach,
Florida
|
-$84.5M |
| 4 |
Renaissance Technologies
New York
|
-$83.1M |
| 5 |
HM
HealthCor Management
New York
|
-$73M |
BIIB Hedge Fund Activity: Q3 2022 in Review
985 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q3 2022, worth a combined $33B — up 32% from $25B a quarter earlier.
Buyers outnumbered sellers: 149 funds opened new BIIB positions and 79 closed out — a net gain of 70 holders — while 275 added to existing stakes and 372 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $260M. The largest seller was Wellington Management Group, cutting an estimated $244M.
- 985 institutional investors held Biogen (BIIB) as of Q3 2022, up from 927 in Q2 2022.
- Funds reported $33B of Biogen stock for Q3 2022, up 32% quarter-over-quarter.
- 149 funds opened new Biogen positions in Q3 2022 and 79 closed out, a net change of +70 holders.
- The largest Biogen buyer in Q3 2022 was Point72 Asset Management, an estimated $260M added.
- The largest Biogen seller in Q3 2022 was Wellington Management Group, an estimated $244M sold.
Based on aggregated 13F filings for Q3 2022.